2022
Atypical Carcinoid Tumor Versus Large-Cell Neuroendocrine Carcinoma
Yoon E, Cai G. Atypical Carcinoid Tumor Versus Large-Cell Neuroendocrine Carcinoma. Practical Anatomic Pathology 2022, 75-81. DOI: 10.1007/978-3-031-14402-8_14.ChaptersLarge cell neuroendocrine carcinomaSmall cell carcinomaAtypical carcinoidNeuroendocrine carcinomaTypical carcinoidHigh-grade malignant neoplasmIntermediate-grade malignancyAtypical carcinoid tumorPulmonary neuroendocrine tumorsSmall biopsy specimensClinical characteristicsCarcinoid tumorsClinicopathologic differencesMalignant neoplasmsNeuroendocrine tumorsBiopsy specimensDifferential diagnosisPleomorphic Carcinoma Versus Sarcomatoid Malignant Mesothelioma
Baine M, Cai G, Zhang X. Pleomorphic Carcinoma Versus Sarcomatoid Malignant Mesothelioma. Practical Anatomic Pathology 2022, 137-145. DOI: 10.1007/978-3-031-14402-8_23.Peer-Reviewed Original ResearchSarcomatoid malignant mesotheliomaPleomorphic carcinomaMalignant mesotheliomaGiant cell carcinomaCell lung carcinomaSmall biopsy specimensPleural involvementPeripheral tumorsClinicopathologic featuresUpper lobeSarcomatoid morphologyCell carcinomaBiopsy specimensLung carcinomaLung parenchymaMalignant tumorsSpindle cellsAnatomic localizationChest wallCarcinomaGiant cellsMesotheliomaLungTumorsCells
2014
Acquired Resistance of EGFR-Mutant Lung Adenocarcinomas to Afatinib plus Cetuximab Is Associated with Activation of mTORC1
Pirazzoli V, Nebhan C, Song X, Wurtz A, Walther Z, Cai G, Zhao Z, Jia P, de Stanchina E, Shapiro EM, Gale M, Yin R, Horn L, Carbone DP, Stephens PJ, Miller V, Gettinger S, Pao W, Politi K. Acquired Resistance of EGFR-Mutant Lung Adenocarcinomas to Afatinib plus Cetuximab Is Associated with Activation of mTORC1. Cell Reports 2014, 7: 999-1008. PMID: 24813888, PMCID: PMC4074596, DOI: 10.1016/j.celrep.2014.04.014.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdenocarcinoma of LungAfatinibAnimalsAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsCell Line, TumorCetuximabDrug Resistance, NeoplasmErbB ReceptorsHumansLung NeoplasmsMechanistic Target of Rapamycin Complex 1MiceMice, NudeMice, TransgenicMultiprotein ComplexesMutationQuinazolinesRandom AllocationTOR Serine-Threonine KinasesXenograft Model Antitumor AssaysConceptsTyrosine kinase inhibitorsFirst-generation tyrosine kinase inhibitorEGFR-mutant lung adenocarcinomaLung adenocarcinomaMechanisms of resistanceEGFR antibody cetuximabPotential therapeutic strategyBiopsy specimensAntibody cetuximabDrug combinationsMouse modelTherapeutic strategiesAfatinibAddition of rapamycinCetuximabDual inhibitionAcquired ResistanceKinase inhibitorsGenomic alterationsAdenocarcinomaPatientsActivationGenomic mechanismsDrugsMTORC1 activation